Back to Trials
NCT07489651PHASE2Recruiting

RE104 Safety and Efficacy Study in Generalized Anxiety Disorder

Reunion Neuroscience Inc

Start Date

4/20/2026

Completion Date

4/1/2027

Summary

The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.

Eligibility Criteria

Age Range: 18 years to 74 years

Inclusion Criteria: * Has Generalized Anxiety Disorder as defined by DSM-5-TR * If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant. * Is willing and able to comply with the conditions and requirements of the study Exclusion Criteria: * Has a significant risk of suicide * Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder * Has other concurrent psychiatric disorders that is the primary disorder. * Has other medically significant conditions rendering unsuitability for the study * Has used or will need to use prohibited medications or therapies * Has a known sensitivity or intolerance to study intervention or potential rescue medications

Interventions

DRUG

RE104 for Injection

DRUG

Placebo

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Generalized Anxiety Disorder

Locations

Lighthouse Psychiatry

Gilbert, Arizona 85234

United States

Preferred Research Partners, Inc.

Little Rock, Arkansas 72211

United States

Collaborative Neuroscience Research, LLC

Garden Grove, California 92845

United States

Kadima Neuropsychiatry Institute

La Jolla, California 92037

United States

Open Mind Therapeutics

San Francisco, California 94114

United States

TRIP Clinic at Psychedelic Science Institute

Santa Monica, California 90404

United States

Innovative Clinical Research, Inc.

Lauderhill, Florida 33319

United States

University of South Florida

Tampa, Florida 33613

United States

Atlanta Center for Medical Research

Atlanta, Georgia 30331

United States

CenExel iResearch, LLC

Decatur, Georgia 30030

United States

Uptown Research Institute

Chicago, Illinois 60640

United States

Henry Ford Medical Center - Columbus

Novi, Michigan 48377

United States

Midwest Research Group

Saint Charles, Missouri 63304

United States

UNM Research Program Psychedelic Therapies

Albuquerque, New Mexico 14624

United States

NYU-H+C Clinical and Translational Science Institute

New York, New York 10016

United States

Neuro-Behavioral Clinical Research, Inc.

North Canton, Ohio 44720

United States

Summit Headlands LLC

Portland, Oregon 97210

United States

Austin Clinical Trial Partners

Austin, Texas 78737

United States

BioBehavioral Research Austion

Austin, Texas 78759

United States

Aim Trials, LLC

Plano, Texas 75093

United States

Cedar Clinical Research

Draper, Utah 84020

United States

Inner Space State Street

Orem, Utah 84058

United States